Personalizing Anticoagulant and Antiplatelet Therapeutics: A Timely Task

Authors

  • David Gurwitz

    Corresponding author
    1. Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    • Correspondence to: David Gurwitz, Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel.

      E-mail: gurwitz@post.tau.ac.il

    Search for more papers by this author

Abstract

In spite of new therapeutics and diagnostics, thrombosis-related diseases including heart failure and stroke remain the leading cause of death globally and a major healthcare burden. Pharmacogenomic studies may reduce the burden of thrombotic diseases by aiding treatment individualization with the most appropriate anti-coagulant and anti-platelet therapeutics. Discovering and validating biomarkers for improved personalized treatment of thrombotic diseases will require massive investment. A concerted dedicated effort built upon a public-private partnership is warranted for addressing this foremost public health concern.

Ancillary